Zephyrx LLC and MIR (Medical International Research) have entered into an exclusive partnership to jointly market the Zephryx Remote Respiratory Monitoring (RRM) Solution, according to a company news release. Through the agreement, the solution becomes the only remote patient monitoring (RPM) solution offered by MIR in North America.
The Zephyrx RRM solution combines a cloud-based provider dashboard with real-time video coaching, patient app, and MIR’s FDA-cleared spirometer.
Zephryx LLC is the largest reseller of MIR’s Spirobank Smart Spirometer and has been working with MIR, a global leader in medical devices and software, since its inception in 2019. With MIR’s well-established customer base and highly qualified sales personnel, MIR is the partner of choice for Zephyrx to fuel its path of accelerating growth, the company says.
“Remote respiratory monitoring has evolved from being a nice-to-have to a necessity since COVID, especially for those with chronic respiratory conditions such as COPD, cystic fibrosis, pulmonary fibrosis, and asthma. But beyond the pandemic, our solution offers improved care models including far greater frequency of monitoring vs. in-clinic appointments, just-in-time respiratory testing, and gamification to support patient adherence. This new partnership greatly expands the visibility of our solutions for customers looking to extend their practice and clinical research beyond its physical walls and into the patient’s home. Just imagine the possibilities,” said Dwight Cheu, Zephyrx CEO.
Dale Novy, MIR National Director of Sales and Business Development, adds “During the past few years, Zephyrx has separated themselves from other RPM companies with a platform that’s a perfect complement to our smart personal spirometers. The COVID pandemic has required patients with chronic respiratory conditions to be monitored differently than in the past. The healthcare industry now, more than ever, needs greater accessibility to tools that allow us to remotely and personally assess our state of respiratory health.”